Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype

NCT05207709 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

456

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Ribociclib + Letrozole OR Fulvestrant
DRUG: Palbociclib + Letrozole OR Fulvestrant
DRUG: Paclitaxel +/- Tislelizumab

Sponsor

SOLTI Breast Cancer Research Group

Collaborators

[object Object]
[object Object]